Dr Paul Mercer

Paul is Head of Collaboration at the Francis Crick Institute and has extensive experience managing industrial collaborations with academia in both the early drug discovery and experimental medicine settings. Most recently he was the programme manager for EMINENT (Experimental Medicine Initiative to Explore New Therapies); a £16M experimental medicine consortium, supported by the MRC and GSK to enable researchers from five leading UK HEIs; utilising GSK assets and expertise in experimental clinical studies in areas of unmet need. As a Principal Research Associate at University College London, Paul worked closely with the Fibrosis DPU at GSK on various targets, most notably as biology lead for repurposing a PI3 kinase inhibitor from oncology the oncology to pulmonary fibrosis. Prior to this Paul completed a postdoc at Novartis Institute for Biomedical Research Horsham following a Pfizer CASE/ MRC award funded PhD in Cell Sciences at the University of Southampton.